Clinical Trial Update: Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

This update reports Phase 2 trial results for recombinant leptin therapy in nonalcoholic steatohepatitis (NASH).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• recombinant leptin (leptin)

Snippet

Sponsor: Elif Oral | Conditions: Fatty Liver Disease, Nonalcoholic | Phase 2 | Status: COMPLETED | Results posted: 2016-12-09